Subscribe
bayer
4 March 2013Patents

India rejects Bayer plea over compulsory licence

India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Patents
A giant’s perspective: interview with Bayer Group
1 November 2013   Protecting IP rights has become a daunting task for pharmaceutical companies in recent years. WIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP.


Editor's picks

Stability attacks Getty’s ‘confected’ case in closing arguments
Artificial Intelligence
Stability attacks Getty’s ‘confected’ case in closing arguments
3 July 2025

Editor's picks

Artificial Intelligence
Stability attacks Getty’s ‘confected’ case in closing arguments
3 July 2025
Trademarks
Ferrari wins Testarossa classic car case at EU court
2 July 2025
Patents
‘We created law’: G1/24 and the creation of the ‘diamond standard’
1 July 2025
Patents
A step too far? Why Stewart’s approach is dividing opinion
20 June 2025
AI
What is an ‘AI training declaration’ and who might need one?
20 June 2025
Future of IP
‘Sad beige’ lawsuit shows how hard it is for influencers to stand out
20 June 2025

More articles

New WIPR Rankings spotlight UK legal market for patents work
Lord Justice Birss to become chancellor of the High Court
‘We created law’: G1/24 and the creation of the ‘diamond standard’
Tech litigators join Hogan Lovells’ Paris practice from A&O Shearman
How in-house patent pros are ‘enablers of innovation’
Smart IP for startups: how to avoid the common traps
Defending the realm: How a key MoD supplier crafts its IP strategy
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations